BRPI0616913A2 - solução, uso de uma solução, kit, e, composição liofilizada - Google Patents

solução, uso de uma solução, kit, e, composição liofilizada

Info

Publication number: BRPI0616913A2
Authority: BR; Brazil
Prior art keywords: solution; freeze; kit; dried composition; dried
Prior art date: 2005-10-07

Application number

BRPI0616913A

Other languages

English (en)

Inventor

Dennis T Mangano

Marwin J Sack

Richard R Stover

Ross Dixon

Sharon Wu

Original Assignee

Pericor Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-07

Filing date

2006-10-03

Publication date

2016-08-23

2006-10-03 Application filed by Pericor Therapeutics Inc filed Critical Pericor Therapeutics Inc

2016-08-23 Publication of BRPI0616913A2 publication Critical patent/BRPI0616913A2/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Inorganic Chemistry (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Neurology (AREA)
Biophysics (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)

BRPI0616913A 2005-10-07 2006-10-03 solução, uso de uma solução, kit, e, composição liofilizada BRPI0616913A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11/246,763 US20070082859A1 (en)	2005-10-07	2005-10-07	Formulations of AICA riboside
PCT/US2006/038692 WO2007044357A2 (en)	2005-10-07	2006-10-03	Formulations of aica riboside

Publications (1)

Publication Number	Publication Date
BRPI0616913A2 true BRPI0616913A2 (pt)	2016-08-23

Family

ID=35735993

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0616913A BRPI0616913A2 (pt)	2005-10-07	2006-10-03	solução, uso de uma solução, kit, e, composição liofilizada

Country Status (12)

Country	Link
US (1)	US20070082859A1 (pt)
EP (1)	EP1933819A4 (pt)
JP (1)	JP2009511476A (pt)
KR (1)	KR20080059632A (pt)
CN (1)	CN101277685A (pt)
AU (1)	AU2006302530A1 (pt)
BR (1)	BRPI0616913A2 (pt)
CA (1)	CA2624073A1 (pt)
GB (1)	GB2430882A (pt)
NO (1)	NO20082098L (pt)
WO (1)	WO2007044357A2 (pt)
ZA (1)	ZA200802646B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2007012045A (es) *	2005-03-28	2008-01-16	Pericor Therapeutics Inc	Composiciones y formulaciones para evitar o reducir efectos adversos a un paciente.
EP3112336B1 (en)	2007-08-08	2018-08-01	Universal Display Corporation	Single triphenylene chromophores in phosphorescent light emitting diodes
WO2009046386A1 (en) *	2007-10-04	2009-04-09	Py Daniel C	Apparatus and method for formulating and aseptically filling liquid products
EP3753565A1 (en) *	2008-10-03	2020-12-23	ViCardia Therapeutics, Inc.	Aica riboside analogs for treatment of cardiac and other conditions
US20120258926A1 (en) *	2009-12-15	2012-10-11	Valentyn Antochshuk	Formulations of acadesine
US10780228B2 (en)	2012-05-07	2020-09-22	Medline Industries, Inc.	Prefilled container systems
US10143703B2 (en) *	2014-01-02	2018-12-04	Massachusetts Eye And Ear Infirmary	Treating ocular neovascularization
US20170349313A1 (en) *	2016-06-01	2017-12-07	Centurion Medical Products Corporation	Methods for manufacturing non-glass prefilled syringes
CN110770720B (zh) *	2017-08-31	2023-11-07	深圳市欢太科技有限公司	资源搜索方法及相关产品

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3271386A (en) *	1964-06-01	1966-09-06	Pfizer & Co C	5-amino-4-imidazolecarboxamide riboside recovery process
JPS4944349B1 (pt) *	1967-06-16	1974-11-27
US4211771A (en) *	1971-06-01	1980-07-08	Robins Ronald K	Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
EP0066909A3 (en) *	1981-05-15	1984-03-07	FISONS plc	Imidazole derivatives, pharmaceutical compositions containing them and processes for their production
US4575498A (en) *	1983-07-21	1986-03-11	Duke University	Method for restoring depleted purine nucleotide pools
US5008251A (en) *	1986-03-27	1991-04-16	The Regents Of The University Of California	Method of treating autism
US4912092A (en) *	1986-03-27	1990-03-27	The Regents Of The University Of California	Methods for increasing extracellular adenosine and for stabilizing mast cells
US5118601A (en) *	1986-03-27	1992-06-02	The Regents Of The University Of California	Method of screening purine nucleoside compounds or analogs for the ability to enhance the cellular synthesis and release of adenosine
US5030623A (en) *	1986-03-27	1991-07-09	The Regents Of The University Of California	Methods for increasing extracellular adenosine and for stabilizing mast cells
US5658889A (en) *	1989-01-24	1997-08-19	Gensia Pharmaceuticals, Inc.	Method and compounds for aica riboside delivery and for lowering blood glucose
US5082829A (en) *	1989-01-24	1992-01-21	Gensia Pharmaceuticals	AICA riboside prodrugs
US5200525A (en) *	1989-01-24	1993-04-06	Gensia Pharmaceuticals	Anti-seizure compounds
US5132291A (en) *	1989-01-24	1992-07-21	Gensia Pharmaceuticals, Inc.	Antivirals and methods for increasing the antiviral activity of azt
US5646128A (en) *	1989-09-15	1997-07-08	Gensia, Inc.	Methods for treating adenosine kinase related conditions
US5187162A (en) *	1989-09-15	1993-02-16	Gensia Pharmaceuticals	Methods of treating neurodegenerative conditions
US5777100A (en) *	1990-08-10	1998-07-07	Gensia Inc.	AICA riboside analogs
IL103294A0 (en) *	1991-09-30	1993-05-13	Gensia Pharma	Pharmaceutical compositions for preventing tissue damage associated with decreased blood flow
US5739141A (en) *	1992-12-16	1998-04-14	Agouron Pharmaceuticals, Inc.	Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds
IL108524A0 (en) *	1993-02-03	1994-05-30	Gensia Inc	Imidazodiazepine analogs
US5366960A (en) *	1993-08-26	1994-11-22	Warner-Lambert Company	Method of treating cerebral and cardiovascular disorders employing [R]3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidaz 0-[4,5-d][1,3]diazepin-8-ol
US20040072138A1 (en) *	1997-11-25	2004-04-15	Medical University Of South Carolina	Attenuation of ischemia/reperfusion injury
US6103702A (en) *	1999-05-24	2000-08-15	Board Of Trustees Of The University Of Illinois	Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome
US20050002943A1 (en) *	2001-10-31	2005-01-06	Oberdan Leo	Amp-kinase agonists or adenosine pro-drugs as immuno-stimulating agents
ES2192495B1 (es) *	2002-03-21	2005-02-16	Universidad De Barcelona	Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).
JP2007516294A (ja) *	2003-12-23	2007-06-21	エムユーエスシーファウンデーションフォーリサーチディベロップメント	炎症性の疾患または症状の予防および治療のための方法および組成物
MX2007012045A (es) *	2005-03-28	2008-01-16	Pericor Therapeutics Inc	Composiciones y formulaciones para evitar o reducir efectos adversos a un paciente.

2005
- 2005-10-07 US US11/246,763 patent/US20070082859A1/en not_active Abandoned
- 2005-12-12 GB GB0525300A patent/GB2430882A/en not_active Withdrawn
2006
- 2006-10-03 CN CNA2006800368534A patent/CN101277685A/zh active Pending
- 2006-10-03 KR KR1020087010896A patent/KR20080059632A/ko not_active Application Discontinuation
- 2006-10-03 JP JP2008534629A patent/JP2009511476A/ja not_active Withdrawn
- 2006-10-03 CA CA002624073A patent/CA2624073A1/en not_active Abandoned
- 2006-10-03 EP EP06816149A patent/EP1933819A4/en not_active Withdrawn
- 2006-10-03 WO PCT/US2006/038692 patent/WO2007044357A2/en active Application Filing
- 2006-10-03 AU AU2006302530A patent/AU2006302530A1/en not_active Abandoned
- 2006-10-03 BR BRPI0616913A patent/BRPI0616913A2/pt not_active IP Right Cessation
2008
- 2008-03-25 ZA ZA200802646A patent/ZA200802646B/xx unknown
- 2008-05-06 NO NO20082098A patent/NO20082098L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2624073A1 (en)	2007-04-19
CN101277685A (zh)	2008-10-01
EP1933819A4 (en)	2009-07-22
KR20080059632A (ko)	2008-06-30
NO20082098L (no)	2008-06-30
JP2009511476A (ja)	2009-03-19
GB0525300D0 (en)	2006-01-18
GB2430882A (en)	2007-04-11
EP1933819A2 (en)	2008-06-25
US20070082859A1 (en)	2007-04-12
ZA200802646B (en)	2009-09-30
WO2007044357A3 (en)	2007-09-27
AU2006302530A1 (en)	2007-04-19
WO2007044357A2 (en)	2007-04-19

Legal Events

Date	Code	Title	Description
2012-03-13	B06G	Technical and formal requirements: other requirements [chapter 6.7 patent gazette]	Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 PAR 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.
2013-01-29	B11Z	Dismissal: petition dismissal - article 216, par 2 of industrial property law	Free format text: REFERENTE A PETICAO NO 20080049839/RJ DE 04/04/2008.
2016-08-09	B11M	Decision cancelled [chapter 11.13 patent gazette]	Free format text: O DESPACHO 11.6.1 DA RPI 2195 DE 29/01/2013 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.
2016-08-16	B06H	Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]	Free format text: O DESPACHO 6.7 DA RPI 2149 DE 13/03/2012 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.
2016-09-27	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES.
2017-01-17	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.
2021-06-08	B350	Update of information on the portal [chapter 15.35 patent gazette]

Publication	Publication Date	Title
FR22C1008I2 (fr)	2024-01-19	Composition immunogène
BRPI0813770A2 (pt)	2014-12-30	Composição, e, uso de uma composição
BRPI0614205A2 (pt)	2016-11-22	composto, composição farmacêutica, e, uso de composto
BRPI0618904A2 (pt)	2016-09-13	composto, composição farmacêutica, e, uso do composto
BRPI0908792A2 (pt)	2015-07-21	Composição, e, uso de uma combinação
BRPI0616913A2 (pt)	2016-08-23	solução, uso de uma solução, kit, e, composição liofilizada
BRPI0609802A2 (pt)	2017-05-02	composto, composição farmacêutica e uso de um composto
BRPI0720211A2 (pt)	2013-12-24	Derivado de indanona, composição, e, uso de uma composição
BRPI0819299A2 (pt)	2014-10-07	Uso de composição, e, composição contendo proteína
NO20055686D0 (no)	2005-12-01	Sammensetning
BRPI0717699A2 (pt)	2014-12-30	"composição e seus processos de preparação, uso de uma composição e uso coméstico de uma composição!
BRPI0821165A2 (pt)	2015-06-16	Uso de uma composição
RU2398586C3 (ru)	2017-10-04	Фармацевтическая композиция
BRPI0813627A2 (pt)	2014-12-23	Peptídio antimicrobiano, composições e métodos de uso
ES2845143T8 (es)	2021-11-17	Composición de trombina estable
BRPI0914793A2 (pt)	2015-08-04	Composição, e, uso de uma composição
BRPI0614730A2 (pt)	2016-11-01	composto, composição farmacêutica, e, uso de um composto
DE602005015634D1 (de)	2009-09-10	Kautschukzusammensetzung
DK1902050T3 (da)	2010-01-04	Oxazolidinonderivater og anvendelse deraf som antibiotika
BRPI0611748A2 (pt)	2016-11-22	composto, composição farmacêutica, e, uso de uma composição farmacêutica
DE602005017191D1 (de)	2009-11-26	Geruchsreduzierte waschstück-zusammensetzung
DE602006014966D1 (de)	2010-07-29	Kautschukzusammensetzung
BRPI0916575A2 (pt)	2015-11-10	composição de graxa lubrificante, e, uso de uma composição de graxa lubrificante
BRPI0813587A2 (pt)	2014-12-30	Composto, uso do mesmo, e, composição farmacêutica
BRPI0615630A2 (pt)	2016-11-16	composição farmacêutica, e, uso de sertindol